Journal of Chemical and Pharmaceutical Research (ISSN : 0975-7384)

header
Reach Us reach to JOCPR whatsapp-JOCPR +44 1625708989
All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Original Articles: 2016 Vol: 8 Issue: 3

Design, synthesis and anticancer activity of novel hybrid compounds of imidazopyridine and quinoline/carbazole

Abstract

A series of novel hybrid compounds of imidazopyridine and quinoline/carbazole derivatives has been prepared and evaluated in vitro against a panel of four human tumor cell lines(viz., cervical HeLa, breast MDA-MB-231, renal ACHN and colon HCT-15). Among them imidazopyridine-quinoline hybrid compounds, 3-(3-benzylimidazo[1,2- a]pyridine-2-yl)-2-chloro-6-methoxyquinoline (8) and 2-chloro-6-methoxy-3-(3-(4-methylbenzylimidazo[1,2- a]pyridine-2-yl)-quinoline (12) showed potent anticancer activity with the IC50 values of(0.34; 0.32; 0.39; 0.31) and (0.35; 0.29; 0.34; 0.30) respectively, 12 being the best among all the compounds synthesized In case of imidazopyridine-carbazole hybrid compounds, 3-(3-benzylimidazo[1,2-a]pyridine-2-yl)-9-ethyl-9H-carbazole(13) showed best activity with the IC50 value of (0.37; 0.41; 0.39; 0.30) followed by compound 9-ethyl-3-(3-4- methylbenzyl)imidazo[1,2-a]pyridine-2-yl)9H-carbazole (17)with the IC50 value of (0.55; 0.49; 0.60; 0.56). This preliminary study discovered that the imidazopyrine scaffold hybridized with quinoline or carbazole could be a good pharmacophore for finding novel and potent anticancer agents.